Novo Nordisk and Eli Lilly presented data extolling the benefits of their relative weight loss therapies in obesity-linked indications, while analysts at BMO Capital Markets were “encouraged” by the strategy communicated by Novo management.
ADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold